Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension

Chest

Volumn 135, Issue 1, 2009, Pages 130-136

  Chin, Kelly M ^a   Channick, Richard N ^b   De Lemos, James A ^a   Kim, Nick H ^b   Torres, Fernando ^a   Rubin, Lewis J ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epoprostenol; Pulmonary hypertension; Thrombocytopenia

Indexed keywords

BOSENTAN; CYCLOPHOSPHAMIDE; FENFLURAMINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; PROSTACYCLIN; STEROID; UNIPROST;

ADULT; ARTICLE; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 58249120510     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-1323     Document Type: Article

References (28)

1. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol with conventional therapy in primary pulmonary hypertension. N Engl J Med 1996; 334:296-301
2. Alheid U, Reichwehr I, Fortermann U. Human endothelial cells inhibit platelet aggregation by stimulating cAMP and cGMP. Eur J Pharmacol 1989; 164:103-110
3. Dickinson NT, Jang EK, Haslam RJ. Activation of cGMP stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelets aggregation. Biochem J 1997; 323:371-377
4. Beghetti M, Reber G, de MP, et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 2002; 19:518-524
5. Rizvi MA, Kojouri K, George JN. Drug-induced thrombocytopenia: an updated systematic review. Ann Intern Med 2001; 134:346
6. Heck J, Keitel K, Wusthoff D, et al. Frequency and pathogenesis of thrombocytopenia in cardiac failure [in German]. Dtsch Med Wochenschr 1976; 101:1381-1384
7. Shah SH, Hayes PC, Allan PL, et al. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis. Am J Gastroenterol 1996; 91:2580-2583
8. Robbins IM, Kawut SM, Yung D, et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 27:578-584
9. Lopes AA, Maeda NY, Ebaid M, et al. Effect of intentional hemodilution on platelet survival in secondary pulmonary hypertension. Chest 1989; 95:1207-1210
10. Jubelirer SJ. Primary pulmonary hypertension: its association with microangiopathic hemolytic anemia and thrombocytopenia. Arch Intern Med 1991; 151:1221-1223
11. Rostagno C, Prisco D, Boddi M. Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J 1991; 4:147-151
12. Steele P, Ellis JH Jr, Weily HS, et al. Platelet survival time in patients with hypoxemia and pulmonary hypertension. Circulation 1977; 55:660-661
13. Peters AM, Rozkovec A, Bell RN, et al. Platelet kinetics in congenital heart disease. Cardiovasc Res 1982; 16:391-397
14. Zahavi J, Zahavi M. Enhanced platelet release reaction, shortened platelet survival time and increased platelet aggregation and plasma thromboxane B2 in chronic obstructive arterial disease. Thromb Haemost 1985; 18:105-109
15. Findlay JY, Plevak DJ, Krowka MJ, et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999; 5:362-365
16. Robbins IM, Gaine SP, Schilz R, et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 117:14-18
17. Horn EM, Barst RJ, Poon M. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 118:1229-1230
18. Hargett CW, Ahearn GS, Krichman AM, et al. Thrombocytopenia associated with chronic intravenous epoprostenol therapy [abstract]. Chest 2004; 126:760S
19. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96:2782-2784
20. Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102:2720-2725
21. Skogby M, Adrian K, Friberg L, et al. The effect of epoprostenol on platelet activation and consumption during experimental extracorporeal perfusion. Artif Organs 1999; 23:984-987
22. Sinzinger H, Horsch AK, Silberbauer K. The behaviour of various platelet function tests during long-term prostacyclin infusion in patients with peripheral vascular disease. Thromb Haemost 1983; 50:885-887
23. Fonseca V, Mikhailidis DP, Boag F, et al. Thrombocytopenia and lupus-like anticoagulant in a patient with peripheral vascular disease: response to infusion of prostacyclin. Angiology 1985; 36:258-263
24. Sasaki Y, Takahashi T, Tanaka I, et al. Expression of prostacyclin receptor in human megakaryocytes. Blood 1997; 99:1039-1046
25. Vittet D, Duperray C, Chevillard C. Cyclic-AMP inhibits cell growth and negatively interacts with platelet membrane glycoprotein expression on the Dami human megakaryoblastic cell line. J Cell Physiol 1995; 163:645-655
26. Shen HW, Chen YL, Chern CY, et al. The effect of prostacyclin agonists on the differentiation of phorbol ester treated human erythroleukemia cells. Prostaglandins Other Lipid Mediat 2007; 83:231-236
27. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172:1586-1589
28. Shapiro S, Hill NS. Transition from IV to subcutaneous prostacyclin: premature withdrawal? Chest 2007; 132:741-743